Evidence for a new boson in the search for the Standard Model Higgs particle decaying to four leptons at CMS

One of the main targets of the CMS experiment is to search for the Standard Model Higgs boson. The 4-lepton channel (from the Higgs decay h->ZZ->4l, l = e,mu) is one of the most promising. The analysis is based on the identification of two opposite-sign, same-flavor lepton pairs: leptons are required to be isolated and to come from the same primary vertex. The Higgs would be statistically revealed by the presence of a resonance peak in the 4-lepton invariant mass distribution. The 4-lepton analysis at CMS is presented, spanning on its most important aspects: lepton identification, variables of isolation, impact parameter, kinematics, event selection, background control and statistical analysis of results. The search leads to an evidence for a signal presence with a statistical significance of more than four standard deviations. The excess of data, with respect to the background-only predictions, indicates the presence of a new boson, with a mass of about 126 GeV/c2 , decaying to two Z bosons, whose characteristics are compatible with the SM Higgs ones.

Advanced aspects of radiation protection in the use of particle accelerators in the medical field

In this work, the well-known MC code FLUKA was used to simulate the GE PETrace cyclotron (16.5 MeV) installed at “S. Orsola-Malpighi” University Hospital (Bologna, IT) and routinely used in the production of positron emitting radionuclides. Simulations yielded estimates of various quantities of interest, including: the effective dose distribution around the equipment; the effective number of neutron produced per incident proton and their spectral distribution; the activation of the structure of the cyclotron and the vault walls; the activation of the ambient air, in particular the production of 41Ar, the assessment of the saturation yield of radionuclides used in nuclear medicine. The simulations were validated against experimental measurements in terms of physical and transport parameters to be used at the energy range of interest in the medical field. The validated model was also extensively used in several practical applications uncluding the direct cyclotron production of non-standard radionuclides such as 99mTc, the production of medical radionuclides at TRIUMF (Vancouver, CA) TR13 cyclotron (13 MeV), the complete design of the new PET facility of “Sacro Cuore – Don Calabria” Hospital (Negrar, IT), including the ACSI TR19 (19 MeV) cyclotron, the dose field around the energy selection system (degrader) of a proton therapy cyclotron, the design of plug-doors for a new cyclotron facility, in which a 70 MeV cyclotron will be installed, and the partial decommissioning of a PET facility, including the replacement of a Scanditronix MC17 cyclotron with a new TR19 cyclotron.